The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study - 05/03/16
, Antonia Calligaro a, Marta Tonello a, Roberta Ramonda a, Antonio Carletto b, Giuseppe Paolazzi c, Roberto Bortolotti c, Teresa Del Ross a, Chiara Grava d, Massimo Boaretto d, Maria Favaro a, Vera Teghil a, Amelia Ruffatti a, Leonardo Punzi aBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 5 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
To evaluate the relevance of anti-adalimumab (anti-ADA) antibodies (Abs) and their relationship with clinical/laboratory features in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
Methods |
Fifty-eight patients affected with RA, AS and PsA were prospectively enrolled. Clinical/laboratory characteristics, disease activity, anti-ADA, anti-nuclear (ANA), anti-double strand (ds)DNA, anti-extractable nuclear antigens (anti-ENA) and anti-phospholipid Abs (aPL) were evaluated at baseline, 4, 12 and 24 weeks of adalimumab treatment.
Results |
Anti-ADA Abs were observed in 11/58 (19%) patients; they were detected within the 4th week of therapy in 90.9% of the positive subjects. Anti-ADA positivity was associated with significantly lower mean adalimumab serum levels (P<0.05). Treatment failure was observed in 20/58 (34.5%) patients and was significantly associated with anti-ADA Abs (P<0.05). Mean adalimumab serum levels were significantly lower in patients with treatment failure than in the responders one, both in the whole cohort (P<0.01) and in the group of anti-ADA positive patients (P<0.01). Adverse events happened more often in anti-ADA positive then in anti-ADA negative patients (27.3% vs 14.9%).
Conclusions |
Anti-ADA abs could be considered an early marker associated to a poor clinical response to adalimumab treatment. Routine ANA/anti-ENA/aPL monitoring did not reveal as useful tools to predict the development of anti-ADA abs.
Le texte complet de cet article est disponible en PDF.Keywords : Anti-adalimumab antibodies, Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis
Plan
Vol 83 - N° 2
P. 167-171 - mars 2016 Retour au numéro
Article précédent
- Short-term efficacy to conventional blind injection versus ultrasound-guided injection of local corticosteroids in tenosynovitis in patients with inflammatory chronic arthritis: A randomized comparative study
- Marwin Gutierrez, Andrea Di Matteo, Marcos Rosemffet, Tomas Cazenave, Gustavo Rodriguez-Gil, Cristina Hernandez Diaz, Lucio Ventura Rios, Natalia Zamora, Maria del Carmen Gonzalez Guzman, Ignacio Carrillo, Tadashi Okano, Fausto Salaffi, Carlos Pineda, Pan-American League against Rheumatisms (PANLAR) Ultrasound Study Group 1
- Paradoxical anti-TNF-associated TB worsening: Frequency and factors associated with IRIS
- Claire Rivoisy, Florence Tubach, Carine Roy, Nathalie Nicolas, Xavier Mariette, Dominique Salmon, Olivier Lortholary, Anne Bourgarit, the RATIO Group 2
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?